Related Experiment Video

Updated: Aug 24, 2026

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

Molecular determinants of altered contractility in heart failure

Xander H T Wehrens1, Andrew R Marks

  • 1Center for Molecular Cardiology, Department of Physiology and Cellular Biophysics, Columbia University College of Physicians and Surgeons, 630W 168th Street, P&S 9-401, Box 65, New York, NY 10032, USA.

Annals of Medicine
|June 5, 2004
PubMed

Insights

Heart failure reduces heart muscle contractility by disrupting calcium handling. Beta-blockers improve contractility by reversing abnormal protein changes in heart failure patients.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Physiology

Background:

  • Heart failure is a major cause of death, characterized by reduced myocardial contractility.
  • Dysfunctional intracellular calcium (Ca2+) handling and excitation-contraction (EC) coupling defects are key in heart failure pathophysiology.
  • Chronic beta-adrenergic signaling leads to cardiac ryanodine receptor (RyR2) hyperphosphorylation, FKBP12.6 dissociation, and altered Ca2+ release.

Purpose of the Study:

  • To investigate the role of beta-adrenergic signaling and RyR2 function in heart failure.
  • To determine the effects of beta-blockers on RyR2 phosphorylation and cardiac contractility.

Main Methods:

  • Analysis of protein alterations in heart failure.
  • Assessment of cardiac ryanodine receptor (RyR2) function and phosphorylation.
  • Evaluation of the impact of beta-blocker treatment on RyR2 and myocardial contractility.

Main Results:

  • Chronic beta-adrenergic stimulation causes RyR2 hyperphosphorylation and FKBP12.6 dissociation, impairing Ca2+ handling.
  • This leads to diastolic sarcoplasmic reticulum (SR) Ca2+ release, SR Ca2+ depletion, and reduced myocardial contractility.
  • Beta-blockers reversed RyR2 hyperphosphorylation and normalized channel function, improving contractility.

Conclusions:

  • Hyperactive beta-adrenergic signaling impairs cardiac Ca2+ handling via RyR2, contributing to reduced contractility in heart failure.
  • Beta-blockers offer therapeutic benefits by restoring RyR2 function and improving myocardial contractility.

More Related Videos

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling08:29

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

Published on: August 1, 2016

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...